- Home
- CHW vs ABSI Comparison
CHW vs ABSI Comparison
Compare CHW & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHW
- ABSI
- Stock Information
- Founded
- CHW 2007
- ABSI 2011
- Country
- CHW United States
- ABSI United States
- Employees
- CHW N/A
- ABSI N/A
- Industry
- CHW Investment Managers
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- CHW Finance
- ABSI Health Care
- Exchange
- CHW Nasdaq
- ABSI Nasdaq
- Market Cap
- CHW 383.8M
- ABSI 353.8M
- IPO Year
- CHW N/A
- ABSI 2021
- Fundamental
- Price
- CHW $6.03
- ABSI $3.09
- Analyst Decision
- CHW
- ABSI Strong Buy
- Analyst Count
- CHW 0
- ABSI 5
- Target Price
- CHW N/A
- ABSI $8.40
- AVG Volume (30 Days)
- CHW 195.2K
- ABSI 3.4M
- Earning Date
- CHW 01-01-0001
- ABSI 05-13-2025
- Dividend Yield
- CHW 9.27%
- ABSI N/A
- EPS Growth
- CHW N/A
- ABSI N/A
- EPS
- CHW N/A
- ABSI N/A
- Revenue
- CHW N/A
- ABSI $4,534,000.00
- Revenue This Year
- CHW N/A
- ABSI $156.33
- Revenue Next Year
- CHW N/A
- ABSI $93.61
- P/E Ratio
- CHW N/A
- ABSI N/A
- Revenue Growth
- CHW N/A
- ABSI N/A
- 52 Week Low
- CHW $5.07
- ABSI $2.01
- 52 Week High
- CHW $6.54
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- CHW 42.46
- ABSI 54.32
- Support Level
- CHW $5.93
- ABSI $2.95
- Resistance Level
- CHW $6.10
- ABSI $3.30
- Average True Range (ATR)
- CHW 0.23
- ABSI 0.28
- MACD
- CHW 0.01
- ABSI 0.12
- Stochastic Oscillator
- CHW 61.82
- ABSI 83.85
About CHW Calamos Global Dynamic Income Fund
Calamos Global Dynamic Income Fund operates as a closed-end management investment company. The company's investment objective is to generate a high level of current income with the objective of capital appreciation. It dynamically allocates its investment among equities, convertible bonds, fixed-income securities and alternative investments.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.